IPO roundup: MAP Pharma’s mixed reception, other recent filings
MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than the $92 million it might have pulled in. Investors, however, reacted positively and pushed up the shares 11 percent to $13.35.
MAP reformulates existing drugs in order to deliver them via inhalers. Its leading product is… Continue Reading
Life sciences briefing: Wednesday, Aug. 22, 2007
Featured companies: Alpex Pharma, Applied Computational Technologies, Separation Design Group, ThermalTherapeutics Systems
Switzerland’s Alpex Pharma raises $9M for plop, plop, fizz, fizz drugs– Alpex Pharma, a Mezzovico, Switzerland drug-formulation company, raised $9 million (CHF 10.9 million) in a second round of funding. Investors included BB Biotech Ventures and Signet Healthcare Partners.
The company essentially reformulates pharmaceuticals for other companies with technologies that make pills melt quickly, allowing them to be taken without water, or to “effervesce” — that… Continue Reading